Score Overview
Explore the 2021 public Archive ranking โ
Where ADMA Biologics Inc has ranked, year by year
Showing 5 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- ADMA
2019: 95.5% ยท 2021: 86.1% ยท free through 2021 ยท longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-30 | $ 10.03 | โ |
1 Year2025-09-30 | $ 14.66 | -31.58% |
5 Years2021-09-30 | $ 1.13 | 8x |
10 Years2016-09-30 | $ 7.24 | 38.54% |
All Time2013-10-17 | $ 8.55 | 17.31% |
| Period | Last Price2026-09-30 | 1 Year2025-09-30 | 5 Years2021-09-30 | 10 Years2016-09-30 | All Time2013-10-17 |
|---|---|---|---|---|---|
| Price | $ 10.03 | $ 14.66 | $ 1.13 | $ 7.24 | $ 8.55 |
| Return | โ | -31.58% | 8x | 38.54% | 17.31% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 512M | $ 168M | $ 136M |
| 2025 | $ 510M | $ 146M | $ 87M |
| 2024 | $ 426M | $ 197M | $ 103M |
| 2023 | $ 258M | -$ 28M | $ 51M |
| 2022 | $ 154M | -$ 65M | $ 86M |
| 2021 | $ 80M | -$ 71M | $ 51M |
| 2020 | $ 42M | -$ 75M | $ 55M |
| 2019 | $ 29M | -$ 48M | $ 26M |
| 2018 | $ 16M | -$ 65M | $ 22M |
| 2017 | $ 22M | -$ 43M | $ 43M |
| 2016 | $ 10M | -$ 19M | $ 15M |
| 2015 | $ 7M | -$ 17M | $ 16M |
| 2014 | $ 5M | -$ 16M | $ 21M |
| IPO2013 | $ 3M | -$ 15M | $ 29M |

ADMA Biologics Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 42M to $ 510M and net income went from -$ 75M to $ 146M. Revenue increased in every one of those 5 years; net income in 4.
Between 2015 and 2025, revenue grew from $ 7M to $ 510M and net income went from -$ 17M to $ 146M. Revenue increased in 9 of those 10 years; net income in 6.
ADMA Biologics Inc currently holds a 5-year HDB Score of 8.5 out of 10. How the HDB Score is calculated.
Membership
Continue ADMAโs history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio




